Digital Counting of Individual Molecules by Stochastic Attachment of Diverse Labels
Abstract
Compositions, methods and kits are disclosed for high-sensitivity single molecule digital counting by the stochastic labeling of a collection of identical molecules by attachment of a diverse set of labels. Each copy of a molecule randomly chooses from a non-depleting reservoir of diverse labels. Detection may be by a variety of methods including hybridization based or sequencing. Molecules that would otherwise be identical in information content can be labeled to create a separately detectable product that is unique or approximately unique in a collection. This stochastic transformation relaxes the problem of counting molecules from one of locating and identifying identical molecules to a series of binary digital questions detecting whether preprogrammed labels are present. The methods may be used, for example, to estimate the number of separate molecules of a given type or types within a sample.
Claims
exact text as granted — not AI-modifiedThat which is claimed is:
1 . A method of determining a presence of an allele of a polymorphic site in a tagged genomic sample, the method comprising:
a) amplifying a population of different target DNA molecules from a tagged genomic sample thereby producing a population of amplified target DNA molecules, wherein:
(i) the different target DNA molecules that comprise a polymorphic site are tagged with different label-tags;
(ii) the label-tags comprise nucleotide bases selected from purine bases, pyrimidine bases, natural nucleotide bases, chemically modified nucleotide bases, biochemically modified nucleotide bases, non-natural nucleotide bases and derivatized nucleotide bases; and
(iii) the amplified target DNA molecules comprise the polymorphic site and an associated label-tag of the label-tags;
b) detecting the population of amplified labeled-targets by sequencing, thereby producing a plurality of readouts, wherein the plurality of readouts comprise (i) the nucleotide sequence of at least a portion of the polymorphic site and (ii) the nucleotide sequence of an associated label-tag; and c) assessing, using a computer, the presence of the allele in the tagged genomic sample, based on:
(i) a determination of a number of the different label-tags that are associated with the allele; and
(ii) a determination of a number of readouts that comprise each of the different label-tags that are associated with the allele.
2 . The method of claim 1 , wherein the assessing step c) further comprises independently assessing the presence of an additional allele of the polymorphic site in the tagged genomic sample based on:
(i) a determination of a number of the different label-tags that are associated with the additional allele of the polymorphic site; and (ii) a determination of a number of readouts that comprise each of the different label-tags that are associated with the additional allele.
3 . The method of claim 1 , wherein the population of different target DNA molecules is produced by ligating a set of adaptors that comprise the label-tags to an initial nucleic acid sample.
4 . The method of claim 3 , wherein the initial nucleic acid sample is an amplification product.
5 . The method of claim 1 , wherein the population of different target DNA molecules is produced by primer extension of a set of primers that comprises the label-tag, using an initial nucleic acid sample as a template.
6 . The method of claim 5 , wherein the initial nucleic acid sample is an amplification product.
7 . The method of claim 1 , wherein the method comprises, prior to the amplifying step (a), enriching the population of different target DNA molecules from an initial nucleic acid sample.
8 . The method of claim 1 , wherein the label-tags comprise at least 2 nucleotide bases, wherein each of the at least 2 nucleotide bases are selected from purine bases, pyrimidine bases, natural nucleotide bases, chemically modified nucleotide bases, biochemically modified nucleotide bases, non-natural nucleotide bases and derivatized nucleotide bases.
9 . The method of claim 8 , wherein the label-tags comprise from 2 to 20 nucleotide bases, wherein each of the 2 to 20 nucleotide bases is selected from purine bases, pyrimidine bases, natural nucleotide bases, chemically modified nucleotide bases, biochemically modified nucleotide bases, non-natural nucleotide bases and derivatized nucleotide bases.
10 . The method of claim 1 , wherein the label-tag is used to correct estimation errors.
11 . The method claim 1 , wherein the different target DNA molecules are further tagged with a unique sequence tag that is used to distinguish target DNA molecules from different samples.
12 . The method of claim 11 , wherein the tagged genomic sample is a mixed sample comprising nucleic acid molecules from different samples, wherein each of the samples is associated with a unique sequence tag that distinguishes the sample of the target DNA molecules to which it is tagged.
13 . The method of claim 12 , wherein each of the samples is derived from a human subject.
14 . The method of claim 12 , wherein each of the samples is derived from a tumor cell.
15 . The method of claim 1 , wherein the tagged genomic sample comprises polynucleotides from a tumor cell.
16 . The method of claim 1 , wherein the tagged genomic sample comprises polynucleotides from bacteria.
17 . The method of claim 1 , wherein the tagged genomic sample comprises human genomic DNA and the polymorphic site comprises a single nucleotide polymorphism of a human genome.
18 . The method of claim 1 , wherein the detecting the population of amplified labeled-targets by sequencing step b) comprises sequencing the amplified target DNA molecules by next-generation sequencing.
19 . The method of claim 1 , wherein the amplifying step a) is done by polymerase chain reaction.
20 . The method of claim 1 , wherein the assessing of step c) comprises performing a statistical analysis.
21 . The method of claim 1 , wherein the method further comprises determining the amount of the allele in the tagged genomic sample.
22 . A method for assessing the presence of an allele of a polymorphic target sequence in a tagged genomic sample, comprising:
a) amplifying a population of different initial target DNA molecules from a tagged genomic sample thereby producing a population of amplified target DNA molecules, wherein the different initial target DNA molecules that comprise a polymorphic target sequence are tagged with different degenerate base region (DBR) sequences, wherein said DBR sequences comprises at least one nucleotide base selected from: R, Y, S, W, K, M, B, D, H, V, N and modified versions thereof and wherein the amplified target DNA molecules comprise said polymorphic target sequence and an associated DBR sequence of said DBR sequences; b) sequencing a plurality of the amplified target DNA molecules, thereby producing a plurality of sequence reads, wherein the sequencing step provides, for each of the amplified target DNA molecules that are sequenced:
(i) the nucleotide sequence of at least a portion of the polymorphic target sequence and
(ii) the nucleotide sequence of an associated DBR sequence;
c) assessing, using a computer, the presence of said allele in said tagged genomic sample, based on:
(i) a determination of the number of said different DBR sequences that are associated with said allele; and
(ii) a determination of the number of said sequence reads that comprise each of the different DBR sequences that are associated with said allele.
23 . The method of claim 22 , wherein: said assessing step c) further comprises independently assessing the presence of an additional allele of the polymorphic target sequence in said tagged genomic sample based on: (i) a determination of the number of said different DBR sequences that are associated with the additional allele of said polymorphic target sequence; and (ii) a determination of the number of said sequence reads that comprise each of the different DBR sequences that are associated with the additional allele.
24 . The method of claim 22 , wherein said population of different initial target DNA molecules is made by ligating a set of adaptors that comprise said DBR sequences to an initial nucleic acid sample.
25 . The method of claim 24 , wherein said initial nucleic acid sample is an amplification product.
26 . The method of claim 22 , wherein said population of different initial target DNA molecules is made by primer extension of a set of primers that comprises said DBR sequences, using an initial nucleic acid sample as a template.
27 . The method of claim 26 , wherein said initial nucleic acid sample is an amplification product.
28 . The method of claim 22 , wherein the method comprises, prior to said amplifying step (a), enriching said population of different initial DNA molecules from an initial nucleic acid sample.
29 . The method of claim 22 , wherein said DBR sequences comprise at least 2 nucleotide bases, wherein each of the at least 2 nucleotide bases are selected from: R, Y, S, W, K, M, B, D, H, V, N, and modified versions thereof.
30 . The method of claim 29 , wherein the DBR sequences comprise from 3 to 20 nucleotide bases, wherein each of the 3 to 10 nucleotide bases is selected from: R, Y, S, W, K, M, B, D, H, V, N, and modified versions thereof.
31 . The method of claim 22 , wherein said DBR sequences comprise an error-correcting code.
32 . The method of claim 22 , wherein the different initial target DNA molecules are further tagged with a unique multiplex identifier (MID) sequence that identifies the source of a nucleic acid molecule to which it is tagged.
33 . The method of claim 32 , wherein said tagged genomic sample is a pooled sample comprising nucleic acid molecules from several different sources, wherein each of said sources is associated with a unique MID sequence that identifies the source of the nucleic acid molecule to which it is tagged.
34 . The method of claim 33 , wherein each of the sources is derived from a human subject.
35 . The method of claim 33 , wherein each of the sources is derived from different parts of a tumor.
36 . The method of claim 33 , wherein each of the sources is derived from a subject at different times.
37 . The method of claim 22 , wherein the tagged genomic sample comprises polynucleotides from a tumor.
38 . The method of claim 22 , wherein the tagged genomic sample comprises polynucleotides from a microorganism and/or a virus.
39 . The method of claim 22 , wherein the tagged genomic sample comprises human genomic DNA and said polymorphic target sequence comprises a single nucleotide polymorphism of a human genome.
40 . The method of claim 22 , wherein said sequencing step b) comprises sequencing said plurality of amplified target DNA molecules on a next-generation sequencing platform.
41 . The method of claim 22 , wherein the amplifying step a) is done by polymerase chain reaction.
42 . The method of claim 22 , wherein the method further assessing step c) comprises performing a maximum likelihood analysis.
43 . The method of claim 22 , wherein the method further comprises determining the amount of the allele in the tagged genomic sample.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.